Krsnaa Diagnostics Limited's Board of Directors has officially approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a five-year term, following recommendations from the Nomination and Remuneration Committee. The decision was formalized during a board meeting held on February 22, 2026, with proper regulatory disclosures filed under SEBI regulations.

Board Meeting Outcome and Regulatory Filing

The board meeting, which commenced at 18:30 Hrs. (IST) and concluded at 21:10 Hrs. (IST), resulted in the formal approval of Mr. Mutha's re-appointment as Whole-time Director and Chairman, designated as Executive Chairman. The company has filed the necessary disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with both stock exchanges.

Re-appointment Terms and Conditions

The Board of Directors has approved Mr. Mutha's re-appointment in accordance with the Companies Act, 2013, SEBI (LODR) Regulations, 2015, and other applicable regulatory provisions. The appointment remains subject to shareholder approval through postal ballot and includes liability to retire by rotation.

Leadership Profile and Industry Expertise

Mr. Rajendra Khivraj Mutha brings over two decades of specialized expertise in pharmacy and diagnostics to his executive role. As a certified Pharmacist accredited by the Maharashtra State Pharmacy Council, he leverages extensive industry knowledge to drive the company's strategic vision and operational excellence.

Beyond operations, he spearheads impactful outreach initiatives focused on community health, women, and children, earning recognition as a changemaker in Indian healthcare. He also leads the company's Corporate Social Responsibility programmes, championing initiatives that uplift underserved communities and reinforce the company's role as a trusted healthcare partner.

Governance and Compliance Standards

The re-appointment maintains proper corporate governance standards, with Mr. Mutha confirmed as not being related to any other Directors on the company's Board. He meets all regulatory compliance requirements and is not debarred from holding directorial positions by SEBI or any other regulatory authority, as confirmed in compliance with SEBI guidelines dated June 14, 2018.

The formal regulatory disclosure has been submitted to both BSE Limited and National Stock Exchange of India Limited, ensuring full transparency and compliance with listing obligations. This re-appointment underscores the board's confidence in Mr. Mutha's ability to continue leading the company's growth trajectory in the competitive healthcare diagnostics market.

Krsnaa Diagnostics Limited has successfully completed the allotment of unlisted secured redeemable non-convertible debentures worth ₹430 crores to the Asian Development Bank. The Operation Committee of the Board of Directors approved this strategic debt financing transaction on February 23, 2026, marking a significant milestone in the company's fundraising initiatives.

Official Allotment Details

The company has formally disclosed the debenture allotment under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The comprehensive structure demonstrates institutional confidence in the company's growth prospects.

Interest and Redemption Structure

The debentures carry an attractive annual interest rate of 7.790% with a well-structured repayment mechanism designed to balance cash flow management with investor returns.

The redemption will occur through thirteen equal installments, with the repayment schedule commencing six months after the allotment date. This grace period provides Krsnaa Diagnostics with adequate time to deploy the raised capital effectively before beginning the repayment cycle.

Regulatory Compliance and Strategic Partnership

The company has fulfilled all regulatory requirements under SEBI guidelines, with the Operation Committee meeting conducted from 14:30 Hrs to 15:00 Hrs on the allotment date. The Asian Development Bank's participation as the sole investor represents a significant endorsement of Krsnaa Diagnostics' business model and growth strategy within the diagnostics sector.

The debentures are secured by charges created over identified assets of the company as per definitive agreements, providing additional security to the institutional investor. This structured debt instrument reflects competitive pricing for secured debt in the current market environment while providing long-term capital stability for expansion and operational requirements.